Glenmark Pharma share rises 3% after four days, here s why
Reversing from 4 days of consecutive fall, Glenmark Pharma stock opened higher at Rs 488 and gained 2.86% to hit the day s high of Rs 497.70 against the last close of Rs 483.85
BusinessToday.In | December 23, 2020 | Updated 16:07 IST
The stock has hit a 52 week high of Rs 572.70 and 52 week low of Rs 168
Glenmark Pharma shares were trading almost 3% higher on Wednesday morning after the Mumbai-based drug firm announced that its Switzerland-based unit, Glenmark Specialty S.A., entered into an exclusive licensing agreement with Menarini Group (Menarini) for Ryaltris.
The company in its press release said Glenmark Specialty has entered into an exclusive licensing agreement with the Menarini Group for commercialising its innovative nasal spray Ryaltris across 33 countries in Europe, including the Balkan region.
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals and Menarini enter into exclusive licensing agreement for commercializing Ryaltris™ nasal spray across numerous markets throughout Europe ANI | Updated: Dec 23, 2020 11:14 IST
Mumbai (Maharashtra) [India] December 23 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd (Glenmark), a research-led global integrated pharmaceutical company, today announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercializing its innovative nasal sprayRyaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for the treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 year
Glenmark to commercialize Ryaltris⢠nasal spray throughout Europe
Glenmark to commercialize Ryaltris⢠nasal spray throughout Europe
23 December 2020 | News
Source credit: Shutterstock
Glenmark Pharmaceuticals Ltd, a research-led global integrated pharmaceutical company, has announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement with Menarini Group (Menarini) for commercialising its innovative nasal spray Ryaltris™ across 33 countries in Europe, including the Balkan region.
Ryaltris™ [olopatadine hydrochloride (665 mcg) and mometasone furoate (25 mcg)], developed by Glenmark, is a novel fixed-dose combination nasal spray of an anti-histamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.
Glenmark Specialty SA, Menarini Group partner to consolidate presence in European market biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.